Minneapolis, MN, USA – The availability of drug delivery partnerships was announced this week at the LifeScience Alley Conference & Expo in Minneapolis, MN, on December 8. These partnership opportunities are based on the development of a new drug delivery formulation by Phillips Company, an FDA-registered Native American owned pharmaceutical manufacturer located in Oklahoma.
In one embodiment, the formulation is combined with tetracycline to create a new topical antibiotic formulation, known as TETRA-ABC. This product kills the most drug-resistant and the most deadly bacteria (such as Staph, MRSA and Acinetobacter) which cause community or hospital acquired infections. Samples are available for evaluation by physicians, hospitals and pharmaceutical companies.
The manufacturer believes this is the world’s strongest broad-spectrum topical antibiotic. The TETRA-ABC topical antibiotic kills all Gram positive and Gram negative bacteria pathogens that have been available for testing.
New drug delivery partnerships are now available, according to Steve Keough, spokesman for Phillips Company. As shown by In-vitro tests, in controlled laboratory conditions, the Zone of Inhibition or kill zone of drugs delivered using the Phillips system is significantly larger than the area where the product is applied. Keough further added, “This drug delivery system makes TETRA-ABC topical antibiotic a best in class pharmaceutical solution, with other applications across multiple fields of use.”
Licensing, development and partnership inquiries: toll free phone 1-888-396-5139 or fax 1-866-542-5773.